Company Overview and News

 
Power Finance Corporation: In a sideways move

2018-10-14 premium.thehindubusinessline
Power Finance Corporation (₹78.6): The stock of Power Finance Corporation had encountered a key long-term resistance in the range between ₹165 and ₹170 in 2014 and again in 2017, and subsequently reversed direction. Since testing this key resistance band in May 2017, the stock has been on a long-term downtrend.
PFC PWQFY CANFINHOME 511196 532810

 
Can Fin Homes Limited - Appointment

2018-10-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
CANFINHOME 511196

 
Can Fin Homes Limited - Updates

2018-10-06 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
CANFINHOME 511196

 
Can Fin Homes Limited - Resignation

2018-10-01 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
CANFINHOME 511196

 
Can Fin Homes Limited - Updates

2018-09-29 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
CANFINHOME 511196

 
Aavas Financiers share sale subscribed 97% on last day

2018-09-27 livemint
Mumbai: The initial public offering (IPO) of Aavas Financiers Ltd was close to fully subscribed on the last day, launched in a week that saw a meltdown in stocks of non-banking finance companies.
DHFL SIFLY 523756 SRI SREINFRA 511072 CANFINHOME 511196 SRIA

 
Can Fin Homes Limited - Updates

2018-09-27 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
CANFINHOME 511196

 
Can Fin Homes Limited - Updates

2018-09-25 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
CANFINHOME 511196

 
D-Street Buzz: Realty stocks plunge with Indiabulls Real Estate down 13%; Biocon hits new 52-week high

2018-09-25 moneycontrol
The Indian stock market continues to trade on a positive note this Tuesday afternoon with the Nifty50 is up 14 points and is trading at 10,981 while the Sensex is trading higher by 135 points at 36,440.
IOC ESL 500325 AUROPHARMA RELIANCE 532617 HINDUNILVR 532832 531795 535789 505200 ALLCARGO ENGINERSIN RIGD 500696 GAILF EICHERMOT 503100 RLNIY YESBANK ECQRY PHOENIXLTD 524804 511072 IDKQY 532749 ATULAUTO JETAIRWAYS CANFINHOME 533264 532648 YYBKY 511196 530965 IBULHSGFIN 532178 DHFL ARBQY GAILY IBREALEST

1
D-Street Buzz: Pharma stocks gain led by Dr Reddy#39;s Labs; HCL Tech hits new 52-week high, DHFL tanks 20%

2018-09-25 moneycontrol
The Indian stock market has witnessed some handsome bounce back as the benchmark indices have regained some lost grounds this Tuesday afternoon. The Nifty50 is up 43 points and is trading at 11,o1o while the Sensex is trading higher by 176 points at 36,481.
ESL INDIANB 533452 532832 531795 535789 EICHERMOT GRUH AXB 524804 511072 JETAIRWAYS CANFINHOME YYBKY 511196 AXBA DHFL TATASTEEL TATLY 500180 IBREALEST WEIZFOREX AUROPHARMA 532617 533273 532814 532215 511288 505200 500470 532187 AXISBANK ENGINERSIN HDFCBANK 500153 503100 YESBANK ECQRY PHOENIXLTD INDUSINDBK IDKQY ATULAUTO 533264 532648 GRHFY AXBKY IBULHSGFIN 532178 OBZIY TTST OBEROIRLTY GANESHBE HDB ARBQY

 
Weakness in NBFCs continue, stocks down 3-22% on liquidity fears

2018-09-25 moneycontrol
The weakness continues in the NBFC (non-banking financial companies) stocks as they were trading lower by 3-22 percent on Tuesday as liquidity fears dragged the share prices.
GRUH 535789 IBULHSGFIN 68HB IDKQY GRHFY CANFINHOME 511196 66HB 64HB 511288 65HB

Related Articles

ALIM: Alimera Sciences Analysis and Research Report

2018-10-01 - Asif

Overview The following discussion and analysis should be read in conjunction with its unaudited interim condensed consolidated financial statements and the related notes that appear elsewhere in this quarterly report on Form 10-Q. This discussion contains forward-looking statements reflecting its current expectations that involve risks and uncertainties. Actual results may differ materially from those discussed in these forward-looking statements due to a number of factors, including those set forth in the section entitled “Risk Factors” in its most recent annual report on Form 10-K. For further information regarding forward-looking statements, please refer to the “Special Note Regarding Forward-Looking Statements and Projections” immediately after the index to this quarterly report on Form 10-Q. Alimera Sciences, Inc., and its subsidiaries (we or Alimera), is a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic pharma...

DMPI: DelMar Pharmaceuticals Analysis and Research Report

2018-09-25 - Asif

Background DelMar Pharmaceuticals, Inc. is a clinical stage drug development company with a focus on the treatment of cancer. The company's mission is to benefit patients and create shareholder value by developing and commercializing anti-cancer therapies for patients whose tumors exhibit features that make them resistant to, or unlikely to respond to, currently available therapies, particularly for orphan cancer indications where patients have failed, or are unlikely to respond to, currently available therapy. DelMar Pharmaceuticals is developing VAL-083, a novel, DNA-targeting agent, for the treatment of glioblastoma multiforme (“GBM”) and potentially other solid tumors, including ovarian cancer. VAL-083 is a first-in-class, DNA-targeting chemotherapeutic that demonstrated activity against a range of tumor types in prior Phase 1 and Phase 2 clinical studies sponsored by the US National Cancer Institute (“NCI”). The company's recent research has highlighted the opportunit...

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...